
    
      Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and
      Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory
      Demyelinating Poly(radiculo)neuropathy ("ProCID trial")
    
  